Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 1, 2022

Study Completion Date

September 4, 2025

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
Interventions
DRUG

Sorafenib

By mouth (PO)

RADIATION

stereotactic body radiation therapy

Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.

Trial Locations (51)

3000

Peter MacCallum Cancer Centre, Melbourne

10032

Columbia University/Herbert Irving Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center - Moses Campus, The Bronx

11794

Stony Brook University Medical Center, Stony Brook

14642

University of Rochester, Rochester

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

23249

Hunter Holmes McGuire Veterans Administration Medical Center, Richmond

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

39216

University of Mississippi Medical Center, Jackson

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

50309

Iowa Methodist Medical Center, Des Moines

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

60153

Loyola University Medical Center, Maywood

60555

Northwestern Medicine Cancer Center Warrenville, Warrenville

60611

Northwestern University, Chicago

60612

University of Illinois, Chicago

62526

Decatur Memorial Hospital, Decatur

63110

Washington University School of Medicine, St Louis

70121

Ochsner Medical Center Jefferson, New Orleans

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

94115

UCSF Medical Center-Mount Zion, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

94704

Alta Bates Summit Medical Center-Herrick Campus, Berkeley

96813

Queen's Medical Center, Honolulu

97213

Providence Portland Medical Center, Portland

98133

ProCure Proton Therapy Center-Seattle, Seattle

98195

University of Washington Medical Center, Seattle

06606

Saint Vincent's Medical Center, Bridgeport

02114

Massachusetts General Hospital Cancer Center, Boston

02118

Boston Medical Center, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

05401

University of Vermont Medical Center, Burlington

T2N 4N2

Tom Baker Cancer Centre, Calgary

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

H2X 3E4

CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal

H3H 2R9

The Research Institute of the McGill University Health Centre (MUHC), Montreal

Unknown

Pamela Youde Nethersole Eastern Hospital, Chai Wan

135-710

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

NRG Oncology

OTHER

lead

Radiation Therapy Oncology Group

NETWORK

NCT01730937 - Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | Biotech Hunter | Biotech Hunter